Development

Novel Purification Method for Oligonucleotides

Oligonucleotides are typically synthesized using the solid-phase phosphoramidite method. However, because the coupling efficiency is less than 100%, base-deletion byproducts are inevitably generated. Single-base deletion byproducts (N-1 mer) must be removed during the purification process, as they may cause off-target effects. Nevertheless, achieving complete removal of N-1mer using conventional purification methods remains challenging due to their physicochemical properties being highly similar to those of the target oligonucleotides.

We are developing an innovative method to separate base-deletion byproducts, exploiting the specific interaction between diols and boronic acids.

※The patent for this purification method has already been applied.

Microphysiological System (MPS)

Traditional drug development faces significant challenges, with high failure rates in clinical trials and escalating costs. Conventional animal models often fail to accurately predict human responses, leading to late-stage failures. Microphysiological systems offer a more human-relevant platform for drug testing, potentially reducing development time and improving success rates.

We are developing a novel MPS in collaboration with the University of Arizona and Ehime University.

Publications